II. Indications

  1. Chemotherapy associated Nausea
  2. Radiation Therapy associated Nausea
  3. Perioperative Nausea and Vomiting

III. Contraindications

IV. Mechanism

  1. Blocks peripheral and central 5HT3 receptors
    1. Peripheral 5HT3 receptors at vagal nerve terminals
    2. Central 5HT3 receptors at ChemoreceptorTrigger Zone in Medulla (area postrema controls Vomiting)

VI. Dosing

  1. Nausea with Chemotherapy
    1. Adult 100 mg orally given 60 minutes before Chemotherapy
    2. Child age 2 to 16 years: 1.8 mg/kg for single dose up to 100 mg orally given 60 minutes before Chemotherapy
  2. Prevention of Surgery Related Nausea (Preoperative)
    1. Given perioperatively for prevention of Nausea or Vomiting
    2. Adult: 100 mg orally taken 2 hours before surgery
    3. Child age 2 to 16 years: 1.2 mg/kg up to 100 mg orally 2 hours before surgery
  3. Surgery Related Nausea or Vomiting (Postoperative)
    1. Given prophylactically 15 min before Anesthesia ends to prevent Postoperative Nausea and Vomiting
    2. Adult: 12.5 mg IV for single dose given 15 minutes before end of Anesthesia
    3. Child: 0.35 mg/kg up to 12.5 mg IV for single dose before end of Anesthesia

VII. Drug Interactions

  1. Cimetidine increases Dolasetron serum levels
  2. Rifampin decreases Dolasetron serum levels

VIII. Safety

  1. Pregnancy Category B
  2. Unknown safety in Lactation

Images: Related links to external sites (from Bing)

Related Studies

Ontology: Dolasetron (C0209210)

Definition (NCI_NCI-GLOSS) The active ingredient in a drug used to treat nausea and vomiting caused by cancer treatment. Dolasetron is a type of serotonin receptor antagonist and a type of antiemetic.
Definition (NCI) An indole derivative and a potent serotonin 5-HT3 receptor antagonist with anti-emetic property. Dolasetron blocks the activity of serotonin released from the enterochromaffin cells of the small intestine by selectively inhibiting and inactivating 5-HT3 receptors located on the nerve terminals of the vagus nerve in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. This results in suppression of signalling to trigger chemo- and radiotherapy induced nausea and vomiting.
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C060344
SnomedCT 108421009, 372488002
English octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl 1H-indole-3-carboxylate, DOLASETRON, dolasetron, Dolasetron, Dolasetron (product), Dolasetron (substance)
Spanish dolasetrón (producto), dolasetrona, dolasetrona (producto), dolasetrona (sustancia), dolasetrón (sustancia), dolasetrón

Ontology: Anzemet (C0718607)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C060344
English Anzemet, anzemet